In its drive to rewrite the rules of the tumor microenvironment so it can capture of the holy grail of successfully battling solid tumors by using T cells, Affini-T Therapeutics Inc. has completed an oversubscribed $175 million. The focus is to develop multiple oncogene driver programs for treating solid tumors such as those with mutated KRAS variants into the clinic, pursue complementary technology licenses to strengthen its cell therapy platform and to optimize its discovery engine.
Spotlight Therapeutics Inc., a company developing cell-targeted in vivo CRISPR gene editing biologics, has raised $36.5 million in series B financing to support advancement of its first-in-class immuno-oncology program and further applications of its in-house technology platform. The financing round was co-led by new investors GordonMD Global Investments and Epiq Capital Group, with participation from Magnetic Ventures, as well as existing investors GV, Emerson Collective and others.
While full details of the underlying science are due to be published in a peer reviewed journal, Kither Biotech Srl has announced its closure of an €18.5 million (US$20.4 million) series B financing with which it aims to translate its approach to rare respiratory diseases into the clinic.
Targeted radiopharmaceutical specialist Precirix NV has closed an €80 million (US$87.8 million) series B financing, enabling it to complete phase II development of CAM-H2, a potential treatment for HER2-positive metastatic breast cancer and gastric cancer. The round follows initial data showing there were no dose limiting toxicities in the first cohort of patients in the phase I/II trial, and a positive review from the safety committee.
RSS
